Strategic Advisory

The global biopharma industry is perpetually evolving in the search for breakthrough therapies, curative drugs, and new treatment pathways. The sheer pace of innovation can be intimidating when making strategic decisions in this hyper dynamic environment.

We serve as growth engines for our clients, advising them on significant matters be it market access, drug discovery, or mergers and acquisitions. Leveraging decades of experience, MP Advisors has been instrumental in accelerating key deals in the global market. These landmark deals speak volumes about our robust network, technical knowledge, and rich experience in devising strategies that have helped our clients achieve better patient outcomes and maximizing their portfolio value.

Our Strategic Advisory Services Include

  • Market Entry Strategy
  • Mergers & Acquisition
  • Growth Strategy
  • Digitization Strategy
  • Product Strategy
  • Joint Venture Partnership
  • Diversification Strategy
  • Product In-licensing/Out-licensing
  • Product Portfolio Selection
  • Product Partnering Strategy

Select Deal/Transaction/Project

  • Indian biologic company acquired by an MNC
  • Sold 35% stake of Indian company to a German company
  • One of the top 10 Indian pharma companies acquired an Indian API company
  • Indian company acquired Austrian API Company
  • Alliance for NCE API sourcing between a US based innovation company and one of the top listed Indian pharma companies
  • First investment of a listed Indian pharma company in an innovation focused US based biotech company
  • Advised one of the top 10 global generics company for Japan market entry
  • Front-end entry in regulated markets for an Indian company, which was primarily a CMO
  • Advised a Global API against an acquisition of a peptide based API company
  • Identified opportunities for in-licensing products in innovative drug delivery systems space
  • Product portfolio selection (API, intermediates/fine chemicals or biologics) for a global Indian pharma company
  • Identified domestic and global rights to in-license products in anti – infective therapy (R & D compounds - NCE and NBE in Phase I, II or III) for one of the top 10 Indian companies